Comparison of outcomes of vancomycin enema vs normal saline enema in management of Hirschprung associated Enterocollitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240730001

Enrollment

Registered

2024-07-30

Start date

2023-08-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hirshprung associated Enterocollitis (HAEC) Enterocolitis, of Hirschsprung disease, HAEC, Clostridium difficile, Vancomycin enema ,normal saline enema

Interventions

In group A patients for per rectal vancomycin therapy, the patient is asked to lie in the left lateral or knee-chest position, and a solution of vancomycin was prepared at a dose of 20-30mg/kg in crys

Experimental Drug,Placebo Comparator Drug

vancomycin group (Group A),Normal saline group (Group B)

Eligibility

Sex/Gender

All

Age

1 Months to 14 Years

Inclusion criteria

Inclusion criteria: All the pre-operative and post-operative Hirschsprung disease patients of age from 1 month to 14 years of age coming with HAEC.

Exclusion criteria

Exclusion criteria: hypersensitive to vancomycin, critically sick patients on arrival, and those with toxic megacolon in which diverting stoma has to be formed.

Design outcomes

Primary

Measure	Time frame
Symptoms resolution sore 1- 10 Hirschsprung Associated Enterocollitis Score	—

Secondary

Measure	Time frame
hospital Stay days days	—

Countries

Pakistan

Contacts

Public ContactNasim khan

LRH-MTI

nasimkhan101@yahoo.com00923459291760

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026